Nairobi, 4 th April 2022: HCG CCK Cancer Centre, a unit of Healthcare Global Enterprises Limited leading oncology chain in India, launched Elekta’s Versa HD™, an advanced linear accelerator designed to treat a broad spectrum of cancers and significantly enhance patient care.
Versa HD will provide clinicians with the dual flexibility to deliver conventional therapies to treat a wide range of tumors, as well as high-precision targeted therapies for treating highly complex cancers. It will help handle the increasing issues of modern-day cancer management while offering patients with best-in-class treatment and high-quality clinical care as an integrated treatment system.
The method will reduce the amount of radiation delivered to healthy tissue while also improving the quality of life. Patients with cancer in Nairobi can now take advantage of the program to improve their treatment outcomes.
“Being the pioneers in adopting advanced technologies for cancer therapies, HCG is proud to introduce Elekta’s Versa HD, yet another market-leading innovation. It has been our ceaseless endeavor to provide personalized and precise cancer treatment to our patients.”
“HCG has been at the forefront of adopting cutting-edge technologies in the fight against cancer and the launch of the Versa HD system is a key milestone in this direction. Equipped with this latest technology, HCG CCK Cancer Centre will be better equipped to provide patient-centric, best-in-class medical services”, said Dr. BS Ajaikumar, Executive Chairman, Healthcare Global Enterprises Limited.
The Elekta Versa HD will cut overall patient treatment time from 5 to 7 weeks for normal treatments to a maximum of 1(one) week, with the overall benefit of significantly reduced treatment side effects in hypofractionated patients.
This is made possible by safeguarding vulnerable organs and healthy tissue. In a single day, the Elekta Versa HD may treat up to 150 patients. Patients who use the Elekta Versa HD will have access to the best outpatient oncology care available in the region, both at HCGCCK and elsewhere.
Patients who currently travel overseas to acquire this specialist treatment yearly would no longer be required to do so because modern treatments would be offered right here in Nairobi, Kenya.
“It is truly commendable that HCG CCK Cancer Centre is the first hospital to introduce this latest technology in the sub-Saharan region of Africa. Elekta’s Versa HD will help improve the quality of life of oncology patients and rationalize treatment costs of tumor diseases in the region.”
“As a leading cancer care specialist, HCG has always been instrumental in bridging the quality and accessibility gap for patients, and with this initiative, we are sure to witness the best treatment outcomes”, said Hon. Dr. Mercy Mwangangi, Chief Administrative Secretary, Ministry of Health, Kenya.
Dr. Manoj Shah, Chairman, MP Shah Hospital, said “Cancer is the second-most cause of mortality across the world, and the launch of Elekta’s Versa HD, will help us provide comprehensive restricted Information and Basic Personal Data
oncology services focused on delivering specialized outcome-based treatments with a multi-disciplinary clinical approach. For the medical team of specialists, this technology will help treat several early to advanced cancers by accurately targeting the most complex tumors.”
Mr. Habib Nehme, Executive Vice President, Elekta, said, “We are excited to collaborate with HCG Cancer hospital, which is committed to enhancing the accessibility of quality cancer care. Elekta is using precision radiation therapy to work towards a future where everyone can benefit from precise and individually tailored radiotherapy treatments.”
“With Versa HD, clinicians can deliver cutting-edge radiation therapy and offer people dealing with cancer a prolonged, disease-free life. Like HCG, our goal is to ensure every patient has access to the best cancer care possible.”